- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05701254
Skeletal Effects of Type 1 Diabetes on Low-Trauma Fracture Risk
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Julie Stubby
- Phone Number: 402-280-4958
- Email: jstubby@creighton.edu
Study Contact Backup
- Name: Joan Lappe
- Phone Number: 402-280-4646
- Email: jmlappe@creighton.edu
Study Locations
-
-
Nebraska
-
Omaha, Nebraska, United States, 68122
- Recruiting
- Creighton University Osteoporosis Research Center
-
Contact:
- Julie Stubby
- Phone Number: 402-280-4958
- Email: jstubby@creighton.edu
-
Contact:
- Joan Lappe
- Phone Number: 402-280-4646
- Email: jmlappe@creighton.edu
-
Sub-Investigator:
- Laura Armas, MD
-
Principal Investigator:
- Mohammed Akhter, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
Criteria for enrollment of female diabetics
- No chronic disease diagnoses that may affect bone, as confirmed by the PI.
- Normal clinical history, physical, and clinical laboratory exam (except for usual complications of a 10+-year diabetic, i.e., ~minimal neuropathy or retinopathy, known, but asymptomatic mild vascular disease, etc.)
- Glomelular Filtration Rate (GFR) >45 ml/min (Renal Association lower limit for "mild" kidney failure).
- Willingness to sign a consent form.
- Willingness to undergo a transilial bone biopsy incision that yields 2 bone specimens.
- No abnormalities in clinical blood chemistry measurements (small, age-related decreases in GFR, will be permitted).
- Caucasian
Criteria for each non-diabetic subject, compared to their matched diabetic:
- Dual-energy x-ray absorptiometry (DXA) measures (BMD, gm/cm) must be within +/- 15% in total hip.
- Body mass index (BMI) must be within +/-10%.
- Age must be within +/- 5 years.
- Caucasian
Exclusion Criteria:
- Women who have had Type 1 diabetes for less than 10 years.
- Non-insulin dependent Type 1 diabetic.
- Less than 50 years old.
- Less than 5 post menopausal.nd have had diabetes for at least 10 years. -
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Type 1 Diabetics
All participants will complete 4 visits over 6-8 weeks.
Visit 1 is a screening visit which includes a physical exam, a bone mineral density scan, a blood draw and an EKG.
Visit 2 consists of dispensing the Tetracycline antibiotic required for the bone biopsy.
Visit 3 is the bone biopsy and includes a blood draw.
Visit 4 is to remove the stitches.
|
The transiliac bone biopsy will be performed on each subject under local anesthesia, and conscious sedation.
From one skin incision located ~2cm posterior and inferior to the anterior-superior pelvic spine on one side of the pelvis, the investigators will obtain two iliac bone specimens, each 7.5 mm in diameter, cylindrical in shape, and including both inner and outer cortices and the intervening trabecular bone.
|
Non-Type 1 Diabetics
All participants will complete 4 visits over 6-8 weeks.
Visit 1 is a screening visit which includes a physical exam, a bone mineral density scan, a blood draw and an EKG.
Visit 2 consists of dispensing the Tetracycline antibiotic required for the bone biopsy.
Visit 3 is the bone biopsy and includes a blood draw.
Visit 4 is to remove the stitches.
|
The transiliac bone biopsy will be performed on each subject under local anesthesia, and conscious sedation.
From one skin incision located ~2cm posterior and inferior to the anterior-superior pelvic spine on one side of the pelvis, the investigators will obtain two iliac bone specimens, each 7.5 mm in diameter, cylindrical in shape, and including both inner and outer cortices and the intervening trabecular bone.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Compare cortical bone tissue levels of pentosidine (AGE), pyridinoline (normal enzymatic collagen crosslinks), and matrix-bound water between T1DM and controls.
Time Frame: 6-8 weeks
|
For different advance glycation endproducts (AGEs), a) pentosidine (PEN), b) pyrinoline (Pyd), and c) tissue water (TW), will be measured using Raman spectroscopy technique on bone biopsy tissue obtained from study participants. Raman spectra will be obtained from the embedded block surfaces using a confocal Raman spectrometer (Renishaw InVia Qontor, www.renishaw.de). These spectra will be collected at the interstitial, cement lines, and actively bone forming osteons with evident fluorescent labels. A continuous laser beam with an excitation of 785 nm and power of 10 mW will be focused through a Raman microscope (Leica DM2700M), using the 50x objective, down to a micrometer-sized spot on the sample.
|
6-8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Compare cortical bone tissue heterogeneity in nanoindentation measures of modulus and hardness between T1DM and controls.
Time Frame: 6- 8 weeks
|
Bone tissue's hardness and modulus will be quantified by using nanoindentation technique. The nanoindentation is a mechanical/material strength testing technique. The technique has been used in bone tissue from bone biopsies.
|
6- 8 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Mohammed Akhter, PhD, Creighton University Osteoporosis Research Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1425624-3
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fractures, Bone
-
Lawson Health Research InstituteCompleted
-
AO Innovation Translation CenterRecruitingLong Bone FracturesUnited States, Canada, Australia, Ghana, Chile, China, Germany, India, Pakistan, Venezuela, Spain, Croatia, Greece
-
University Hospital, Clermont-FerrandRecruiting
-
Centre Hospitalier Universitaire Saint PierreRecruiting
-
McMaster UniversityMcMaster Surgical AssociatesCompleted
-
University of UtahCompletedBone Strength | Stress Fractures | Bone Geometry | Biomechanical ChangesUnited States
-
IlluminOss Medical, Inc.CompletedHumerus Fracture Metastatic Bone DiseaseUnited States
-
University of British ColumbiaCompleted
-
Novo Nordisk A/SCompletedBone Fracture | Tibia FracturesIsrael, Germany, Finland, Hungary, Spain, South Africa, Norway, France, Poland
-
Carlos A Acosta-OlivoCompletedRadius Fractures | Bone Fractures | Closed Fractures
Clinical Trials on Transilial bone biopsy
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingHematopoietic and Lymphoid System NeoplasmUnited States
-
Postgraduate Institute of Medical Education and...Completed
-
Duke UniversitySuspendedKidney Cancer | Prostate Cancer | Bladder Cancer | Genito Urinary CancerUnited States
-
Medical College of WisconsinRecruitingBone Marrow Biopsy ProcedureUnited States
-
Hospices Civils de LyonUnknown
-
Vidacare CorporationCompletedBone Marrow Biopsy ProceduresUnited States, Spain
-
Ditte HansenUniversity of Copenhagen; Universiteit AntwerpenRecruitingRenal OsteodystrophyDenmark
-
Vidacare CorporationCompletedBone Marrow Aspiration and Biopsy Specimen CollectionUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI); Incuron LLCRecruitingRefractory Lymphoma | Refractory Malignant Solid Neoplasm | Recurrent Lymphoma | Recurrent Malignant Solid Neoplasm | Recurrent Osteosarcoma | Refractory Osteosarcoma | Diffuse Midline Glioma, H3 K27M-Mutant | Recurrent Diffuse Intrinsic Pontine Glioma | Metastatic Malignant Neoplasm in the Central... and other conditionsUnited States
-
University of Michigan Rogel Cancer CenterTerminatedMetastatic Breast CancerUnited States